Summary
Background We have assessed the safety and immunogenicity of the COVID-19 vaccine MVC-COV1901, a recombinant protein vaccine containing prefusion-stabilized spike protein S-2P adjuvanted with CpG 1018 and aluminium hydroxide.
Methods This is a phase 2, prospective, randomised, double-blind, placebo-controlled, and multi-centre study to evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 vaccine candidate MVC-COV1901. The study comprised 3,844 participants of ≥ 20 years who were generally healthy or with stable pre-existing medical conditions. The study participants were randomly assigned in a 6:1 ratio to receive either MVC-COV1901 containing 15 μg of S-2P protein or placebo containing saline. Participants received two doses of MVC-COV1901 or placebo, administered 28 days apart via intramuscular injection. The primary outcomes were to evaluate the safety, tolerability, and immunogenicity of MVC-COV1901 from Day 1 (the day of first vaccination) to Day 57 (28 days after the second dose). Immunogenicity of MVC-COV1901 was assessed through geometric mean titres (GMT) and seroconversion rates (SCR) of neutralising antibody and antigen-specific immunoglobulin. This clinical trial is registered at ClinicalTrials.gov: NCT04695652.
Findings From the start of this phase 2 trial to the time of interim analysis, no vaccine-related Serious Adverse Events (SAEs) were recorded. The most common solicited adverse events across all study participants were pain at the injection site (64%), and malaise/fatigue (35%). Fever was rarely reported (<1%). For all participants in the MVC-COV1901 group, at 28 days after the second dose against wild type SARS-CoV-2 virus, the GMT was 662·3 (408 IU/mL), the GMT ratio was 163·2, and the seroconversion rate was 99·8%.
Interpretation MVC-COV1901 shows good safety profiles and promising immunogenicity responses. The current data supports MVC-COV1901 to enter phase 3 efficacy trials and could enable regulatory considerations for Emergency Use Authorisation (EUA).
Funding Medigen Vaccine Biologics Corporation and Taiwan Centres for Disease Control.
Competing Interest Statement
Hsieh SM, Liu Mc, Chen YS, Lee WS, Hwang SJ, Cheng SH, Ko WC, Hwang KP, Wang NC, Lee YL, Lin YL, Shih SR, Huang CG, Liao CC, Liang JJ, Chang CS and Lin TY declared that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper;, Chen C, Lien CE, Tai IC are employee of Medigen Vaccine Biologics Corporation and reported grants from Taiwan Centers for Disease Control, Ministry of Health and Welfare, during the conduct of the study. In addition, Chen C has a patent US63/040,696 pending.
Clinical Trial
NCT04695652
Funding Statement
Medigen Vaccine Biologics Corp. (MVC) is the sponsor of the study and manufactured the investigational vaccine MVC-COV1901, in cGMP standard. The sponsor co-designed the trial and coordinated interactions with the contract clinical research organization (CRO) staff, and regulatory authorities. The CRO took charge of trial operation to meet the required standard for The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) and Good Clinical Practice (GCP). The IDMC oversees the safety data and gives recommendations to the sponsor. The interim analysis was performed by the CRO. Taiwan Centres for Disease Control (CDC) of the Ministry of Health and Welfare provided grant funding and guidance for design of this study, but had no role in data collection, data analysis, data interpretation, or drafting of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial protocol and informed consent form were approved by Taiwan Food and Drug Administration (TFDA) and the ethics committees at the conducting sites (Main review Institutional. Review Board [IRB]: Chang Gung Medical Foundation; sub Review IRBs: National Taiwan University Hospital; Taipei Veterans General Hospital, Tri-Service General Hospital, Taipei Medical University Hospital, Taipei Municipal Wanfang Hospital, Taoyuan General Hospital MOHW, China Medical University Hospital, Changhua Christian Hospital, National Cheng Kung University Hospital, and Kaoshiung Medical University Hospital) An Independent Data Monitoring Committee (IDMC) was established to monitor data safety and trial conduct.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon reasonable request
